Osteoporosis following spinal cord injury (SCI) is well known and is indicated by low bone mass with a deterioration of skeletal micro-architecture. Disuse osteoporosis is considered as the underlying cause of osteoporosis following acute SCI. Intravenous bisphosphonates are more advantageous than oral compounds (such as alendronate) in patients with SCI. Zoledronic acid is a third-generation bisphosphonate with a more potent ability to suppress osteoclast-mediated bone resorption than its congeners.
Furthermore, zoledronic acid needs to be administered only once annually via intravenous infusion. The present clinical article aims to highlight a clinical trial evaluating the effect of early administration of zoledronic acid infusion on the reduction of bone loss in patients with acute SCI. Trial Objective: To determine the outcome of Zoledronic acid on bone loss in patients with SCI.…
